PensionDanmark Pensionsforsikringsaktieselskab cut its holdings in Corteva, Inc. (NYSE:CTVA – Free Report) by 19.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 146,962 shares of the company’s stock after selling 35,576 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Corteva were worth $12,446,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the business. JPL Wealth Management LLC purchased a new position in Corteva in the third quarter worth about $25,000. Garton & Associates Financial Advisors LLC purchased a new stake in Corteva during the fourth quarter valued at approximately $27,000. Bank of Jackson Hole Trust purchased a new stake in Corteva during the fourth quarter valued at approximately $28,000. Cornerstone Financial Management LLC bought a new stake in shares of Corteva in the 4th quarter valued at approximately $29,000. Finally, Basepoint Wealth LLC purchased a new position in shares of Corteva in the 4th quarter worth approximately $30,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.
Corteva Stock Performance
Shares of Corteva stock opened at $76.95 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average is $81.93 and its two-hundred day moving average is $79.82. Corteva, Inc. has a 52 week low of $60.53 and a 52 week high of $90.97. The company has a market capitalization of $51.34 billion, a PE ratio of 50.96, a price-to-earnings-growth ratio of 2.36 and a beta of 0.57.
Corteva Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be issued a dividend of $0.18 per share. The ex-dividend date is Tuesday, September 1st. This represents a $0.72 dividend on an annualized basis and a yield of 0.9%. Corteva’s dividend payout ratio (DPR) is presently 47.68%.
Wall Street Analyst Weigh In
Several analysts recently weighed in on CTVA shares. Bank of America increased their price target on Corteva from $90.00 to $96.00 and gave the company a “buy” rating in a report on Monday, July 20th. The Goldman Sachs Group boosted their price objective on shares of Corteva from $88.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Citigroup increased their target price on shares of Corteva from $85.00 to $86.00 and gave the company a “neutral” rating in a research note on Monday. Mizuho raised their target price on shares of Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Finally, Oppenheimer lifted their price target on shares of Corteva from $89.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Corteva has a consensus rating of “Moderate Buy” and a consensus price target of $91.70.
Check Out Our Latest Stock Analysis on Corteva
Corteva Company Profile
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
See Also
- Five stocks we like better than Corteva
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.
